Francis  Lo net worth and biography

Francis Lo Biography and Net Worth

Francis Lo is the Chief People Officer of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Francis brings a unique, multi-disciplinary perspective to leading People and Culture at Adaptive. Prior to joining Adaptive, Francis served as Vice President of Human Resources at Whole Foods Market. Previously, he also held leadership roles at Starbucks, including as Director of Global Talent Management and as Dean of Starbucks China University. In addition to his HR experience, Francis has worked in CPG Sales, Strategy, Consumer Insights, and Shopper Marketing, and he has served on the boards of multiple Non-Profit Organizations. Francis holds an MBA from Stanford University Graduate School of Business and a BA in the Plan II Honors Program from the University of Texas at Austin.

What is Francis Lo's net worth?

The estimated net worth of Francis Lo is at least $60,578.72 as of May 14th, 2021. Mr. Lo owns 22,604 shares of Adaptive Biotechnologies stock worth more than $60,579 as of April 26th. This net worth evaluation does not reflect any other investments that Mr. Lo may own. Learn More about Francis Lo's net worth.

How old is Francis Lo?

Mr. Lo is currently 43 years old. There are 7 older executives and no younger executives at Adaptive Biotechnologies. The oldest executive at Adaptive Biotechnologies is Ms. Stacy L. Taylor, Senior VP, General Counsel & Corporate Secretary, who is 64 years old. Learn More on Francis Lo's age.

How do I contact Francis Lo?

The corporate mailing address for Mr. Lo and other Adaptive Biotechnologies executives is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. Adaptive Biotechnologies can also be reached via phone at (206) 659-0067 and via email at [email protected]. Learn More on Francis Lo's contact information.

Has Francis Lo been buying or selling shares of Adaptive Biotechnologies?

Francis Lo has not been actively trading shares of Adaptive Biotechnologies during the last quarter. Most recently, Francis Lo sold 2,000 shares of the business's stock in a transaction on Friday, May 14th. The shares were sold at an average price of $33.80, for a transaction totalling $67,600.00. Following the completion of the sale, the insider now directly owns 22,604 shares of the company's stock, valued at $764,015.20. Learn More on Francis Lo's trading history.

Who are Adaptive Biotechnologies' active insiders?

Adaptive Biotechnologies' insider roster includes R. Adams (COO), Lance Baldo (Insider), Sharon Benzeno (Insider), Chad Cohen (CFO), Egon Durban (Director), David Goel (Director), Michelle Griffin (Director), Francis Lo (Insider), Jyoti Palaniappan (SVP), Chad Robins (CEO), Chad Robins (CEO), Harlan Robins (Insider), Julie Rubinstein (President), and Stacy Taylor (SVP). Learn More on Adaptive Biotechnologies' active insiders.

Are insiders buying or selling shares of Adaptive Biotechnologies?

During the last twelve months, insiders at the sold shares 10 times. They sold a total of 373,179 shares worth more than $2,435,243.14. The most recent insider tranaction occured on March, 5th when insider Kyle Piskel sold 7,727 shares worth more than $26,503.61. Insiders at Adaptive Biotechnologies own 5.2% of the company. Learn More about insider trades at Adaptive Biotechnologies.

Information on this page was last updated on 3/5/2024.

Francis Lo Insider Trading History at Adaptive Biotechnologies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/14/2021Sell2,000$33.80$67,600.0022,604View SEC Filing Icon  
4/15/2021Sell2,000$43.04$86,080.0022,604View SEC Filing Icon  
2/16/2021Sell2,000$65.45$130,900.002,000View SEC Filing Icon  
1/15/2021Sell2,000$66.55$133,100.002,000View SEC Filing Icon  
11/16/2020Sell2,000$47.68$95,360.002,000View SEC Filing Icon  
10/12/2020Sell25,000$52.80$1,320,000.0025,000View SEC Filing Icon  
8/17/2020Sell2,000$39.36$78,720.002,000View SEC Filing Icon  
7/15/2020Sell2,000$43.86$87,720.002,000View SEC Filing Icon  
6/18/2020Sell2,000$44.34$88,680.002,000View SEC Filing Icon  
See Full Table

Francis Lo Buying and Selling Activity at Adaptive Biotechnologies

This chart shows Francis Lo's buying and selling at Adaptive Biotechnologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Adaptive Biotechnologies Company Overview

Adaptive Biotechnologies logo
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $2.68
Low: $2.56
High: $2.73

50 Day Range

MA: $3.26
Low: $2.34
High: $4.27

2 Week Range

Now: $2.68
Low: $2.28
High: $9.08

Volume

191,682 shs

Average Volume

1,611,817 shs

Market Capitalization

$388.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25